Castle Biosciences Announces Availability of DecisionDx-Melanoma Test to Identify Stage I & II Melanoma Patients at High Risk of Metastasis
6/3/2013 11:09:05 AM
More...
|
Castle Biosciences Licenses Thymoma Test Technology; Availability on Track for End of 1st Quarter of 2012
1/25/2012 8:58:23 AM
More...
|
Castle Biosciences Announces Availability of DecisionDx-GBM Biomarker Test for Brain Cancer (Glioblastoma Multiforme) Patients that Predicts Overall Survival to First-Line Standard of Care Treatment
7/16/2009 11:43:06 AM
More...
|
Castle Biosciences, a Biomarker Based Cancer Diagnostics Company, Announces Appointment of Derek Maetzold as President and CEO
9/26/2008 8:27:19 AM
More...
|